News

SEATTLE and VANCOUVER, British Columbia, October 3, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that management will be participating at two upcoming investor conferences. Meetings will be conducted at the JonesTrading…

SEATTLE and VANCOUVER, British Columbia, September 7, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that John Bencich, CEO of Achieve, will be participating at three upcoming conferences. H.C. Wainwright 25th Annual…

Company to host conference call tomorrow, Tuesday, August 15, 2023, at 8:30 AM EDT. SEATTLE, Wash and VANCOUVER, British Columbia, August 14, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced second quarter…

SEATTLE, WA and VANCOUVER, British Columbia, August 1, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its second quarter 2023 financial results on Monday, August 14, 2023, and…

SEATTLE and VANCOUVER, British Columbia, June 6, 2023 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that John Bencich, CEO of Achieve, will be presenting at the LD Micro Invitational XIII in Los…